QUILT-3.006 for Recurrent Medullary Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 26, 2013

Primary Completion Date

May 8, 2018

Study Completion Date

May 8, 2018

Conditions
Medullary Thyroid Cancer (MTC)
Interventions
BIOLOGICAL

GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]

GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.

Trial Locations (1)

20892

NIH Clinical Center, Bethesda

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

NantCell, Inc.

INDUSTRY

NCT01856920 - QUILT-3.006 for Recurrent Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter